UNLABELLED: ESSENTIALS: Anti-factor VIII (FVIII) inhibitory antibody formation is a severe complication in hemophilia A therapy. We genetically engineered and characterized a mouse model with complete deletion of the F8 coding region. F8(TKO) mice exhibit severe hemophilia, express no detectable F8 mRNA, and produce FVIII inhibitors. The defined background and lack of FVIII in F8(TKO) mice will aid in studying FVIII inhibitor formation. BACKGROUND: The most important complication in hemophilia A treatment is the development of inhibitory anti-Factor VIII (FVIII) antibodies in patients after FVIII therapy. Patients with severe hemophilia who express no endogenous FVIII (i.e. cross-reacting material, CRM) have the greatest incidence of inhibitor formation. However, current mouse models of severe hemophilia A produce low levels of truncated FVIII. The lack of a corresponding mouse model hampers the study of inhibitor formation in the complete absence of FVIII protein. OBJECTIVES: We aimed to generate and characterize a novel mouse model of severe hemophilia A (designated the F8(TKO) strain) lacking the complete coding sequence of F8 and any FVIII CRM. METHODS: Mice were created on a C57BL/6 background using Cre-Lox recombination and characterized using in vivo bleeding assays, measurement of FVIII activity by coagulation and chromogenic assays, and anti-FVIII antibody production using ELISA. RESULTS: All F8 exonic coding regions were deleted from the genome and no F8 mRNA was detected in F8(TKO) mice. The bleeding phenotype of F8(TKO) mice was comparable to E16 mice by measurements of factor activity and tail snip assay. Similar levels of anti-FVIII antibody titers after recombinant FVIII injections were observed between F8(TKO) and E16 mice. CONCLUSIONS: We describe a new C57BL/6 mouse model for severe hemophilia A patients lacking CRM. These mice can be directly bred to the many C57BL/6 strains of genetically engineered mice, which is valuable for studying the impact of a wide variety of genes on FVIII inhibitor formation on a defined genetic background.
UNLABELLED: ESSENTIALS: Anti-factor VIII (FVIII) inhibitory antibody formation is a severe complication in hemophilia A therapy. We genetically engineered and characterized a mouse model with complete deletion of the F8 coding region. F8(TKO) mice exhibit severe hemophilia, express no detectable F8 mRNA, and produce FVIII inhibitors. The defined background and lack of FVIII in F8(TKO) mice will aid in studying FVIII inhibitor formation. BACKGROUND: The most important complication in hemophilia A treatment is the development of inhibitory anti-Factor VIII (FVIII) antibodies in patients after FVIII therapy. Patients with severe hemophilia who express no endogenous FVIII (i.e. cross-reacting material, CRM) have the greatest incidence of inhibitor formation. However, current mouse models of severe hemophilia A produce low levels of truncated FVIII. The lack of a corresponding mouse model hampers the study of inhibitor formation in the complete absence of FVIII protein. OBJECTIVES: We aimed to generate and characterize a novel mouse model of severe hemophilia A (designated the F8(TKO) strain) lacking the complete coding sequence of F8 and any FVIII CRM. METHODS:Mice were created on a C57BL/6 background using Cre-Lox recombination and characterized using in vivo bleeding assays, measurement of FVIII activity by coagulation and chromogenic assays, and anti-FVIII antibody production using ELISA. RESULTS: All F8 exonic coding regions were deleted from the genome and no F8 mRNA was detected in F8(TKO) mice. The bleeding phenotype of F8(TKO) mice was comparable to E16mice by measurements of factor activity and tail snip assay. Similar levels of anti-FVIII antibody titers after recombinant FVIII injections were observed between F8(TKO) and E16mice. CONCLUSIONS: We describe a new C57BL/6 mouse model for severe hemophilia Apatients lacking CRM. These mice can be directly bred to the many C57BL/6 strains of genetically engineered mice, which is valuable for studying the impact of a wide variety of genes on FVIII inhibitor formation on a defined genetic background.
Authors: L N Nielsen; B Wiinberg; M Häger; H L Holmberg; J J Hansen; K Roepstorff; M Tranholm Journal: J Thromb Haemost Date: 2014-08 Impact factor: 5.824
Authors: Shannon L Meeks; Courtney L Cox; John F Healey; Ernest T Parker; Bhavya S Doshi; Bagirath Gangadharan; Rachel T Barrow; Pete Lollar Journal: Blood Date: 2012-07-31 Impact factor: 22.113
Authors: Seema R Patel; Taran S Lundgren; Wallace Hunter Baldwin; Courtney Cox; Ernest T Parker; John F Healey; Ryan P Jajosky; Patricia E Zerra; Cassandra D Josephson; Christopher B Doering; Sean R Stowell; Shannon L Meeks Journal: Front Immunol Date: 2022-05-11 Impact factor: 8.786
Authors: M Neale Weitzmann; Susanne Roser-Page; Tatyana Vikulina; Daiana Weiss; Li Hao; W Hunter Baldwin; Kanglun Yu; Natalia Del Mazo Arbona; Meghan E McGee-Lawrence; Shannon L Meeks; Christine L Kempton Journal: Blood Adv Date: 2019-02-12
Authors: Patricia E Zerra; Courtney Cox; W Hunter Baldwin; Seema R Patel; Connie M Arthur; Pete Lollar; Shannon L Meeks; Sean R Stowell Journal: Blood Date: 2017-10-04 Impact factor: 22.113
Authors: Patricia E Zerra; Connie M Arthur; Satheesh Chonat; Cheryl L Maier; Amanda Mener; Sooncheon Shin; Jerry William L Allen; W Hunter Baldwin; Courtney Cox; Hans Verkerke; Ryan P Jajosky; Christopher A Tormey; Shannon L Meeks; Sean R Stowell Journal: Front Immunol Date: 2020-06-09 Impact factor: 7.561
Authors: Junjiang Sun; Xiaojing Chen; Zheng Chai; Hongqian Niu; Amanda L Dobbins; Timothy C Nichols; Chengwen Li Journal: Front Med (Lausanne) Date: 2022-08-05
Authors: Patricia E Zerra; Ernest T Parker; Wallace Hunter Baldwin; John F Healey; Seema R Patel; James W McCoy; Courtney Cox; Sean R Stowell; Shannon L Meeks Journal: Biomedicines Date: 2022-07-18
Authors: Katarzyna I Jankowska; Maitreyi Chattopadhyay; Zuben E Sauna; Chintamani D Atreya Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923